# Efficacy and Safety of Sublingual Immunotherapy (SLIT)

> **NCT01012882** · PHASE3 · UNKNOWN · sponsor: **Roxall Medizin** · enrollment: 120 (estimated)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **BIOLOGICAL:** sublingual immunotherapy with allergen extract
- **BIOLOGICAL:** sublingual immunotherapy with placebo

## Key facts

- **NCT ID:** NCT01012882
- **Lead sponsor:** Roxall Medizin
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2015-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01012882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01012882, "Efficacy and Safety of Sublingual Immunotherapy (SLIT)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01012882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*